The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies
Abstract
PURPOSE: To evaluate the toxicity, pharmacokinetics, immunogenicity, and antitumor activity of anti-Tac(Fv)-PE38 (LMB-2), an anti-CD25 recombinant immunotoxin that contains an antibody Fv fragment fused to truncated Pseudomonas exotoxin. PATIENTS AND METHODS: Patients with CD25+hematologic malignancies for whom standard and salvage therapies failed were treated with LMB-2 at dose levels that ranged from 2 to 63 μg/kg administered intravenously over 30 minutes on alternate days for three doses (QOD × 3). RESULTS: LMB-2 was administered to 35 patients for a total of 59 cycles. Dose-limiting toxicity at the 63 μg/kg level was reversible and included transaminase elevations in one patient and diarrhea and cardiomyopathy in another. LMB-2 was well tolerated in nine patients at the maximum-tolerated dose (40 μg/kg QOD × 3); toxicity was transient and most commonly included transaminase elevations (eight patients) and fever (seven patients). Only six of 35 patients developed significant neutralizing antibodies after the first cycle. The median half-life was 4 hours. One hairy cell leukemia (HCL) patient achieved a complete remission, which is ongoing at 20 months. Seven partial responses were observed in cutaneous T-cell lymphoma (one patient), HCL (three patients), chronic lymphocytic leukemia (one patient), Hodgkin’s disease (one patient), and adult T-cell leukemia (one patient). Responding patients had 2 to 5 log reductions of circulating malignant cells, improvement in skin lesions, and regression of lymphomatous masses and splenomegaly. All four patients with HCL responded to treatment. CONCLUSION: LMB-2 has clinical activity in CD25+hematologic malignancies and is relatively nonimmunogenic. It is the first recombinant immunotoxin to induce major responses in cancer. LMB-2 and similar agents that target other cancer antigens merit further clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,593
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.
Allured, V. S., Collier, R. J., Carroll, S. F., & McKay, D. B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.5.1320 · Cited by 515
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
Chaudhary, V. K., Queen, G., Junghans, R. P., Waldmann, T. A., FitzGerald, D. J., & Pastan, I. (1989) · Nature · doi:10.1038/339394a0 · Cited by 413
Self-citationLong-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment
Saven, A., Burian, C., Koziol, J. A., & Piro, L. D. (1998) · Blood · doi:10.1182/blood.v92.6.1918 · Cited by 329
Nussenblatt, R. B., Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7462 · Cited by 259
Self-citationAmlot, P., Stone, M., Cunningham, D., Fay, J., Newman, J., Collins, R., May, R., McCarthy, M., Richardson, J., & Ghetie, V (1993) · Blood · doi:10.1182/blood.v82.9.2624.2624 · Cited by 235
LeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F. M., Platanias, L. C., Schwartz, G. N., Ratain, M. J., Rook, A. H., Freytes, C. O., Craig, F. E., et al. (1998) · PubMed · doi:10.1182/blood.v91.2.399 · Cited by 184
Cited by
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
EGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan, C. T., Wikstrand, C. J., & Bigner, D. D. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080083 · Cited by 323
Advances in interleukin 2 receptor targeted treatment
Morris, J. C., & Waldmann, T. A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.suppl_1.i109 · Cited by 131
Self-citationLiu, C., Kobashigawa, Y., Yamauchi, S., Toyota, Y., Teramoto, M., Ikeguchi, Y., Fukuda, N., Sato, T., Sato, Y., Kimura, H., et al. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz059 · Cited by 15
Metadata
- Authors
- Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., & Pastan, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-08
- Volume
- 18
- Issue
- 8
- Pages
- 1622-1636
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112628345
- Cited by
- 420
- References
- 30
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. https://app.cochat.ai/papers/10.1200/jco.2000.18.8.1622
- The paper
- Kreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., & Pastan, I. (2000). Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.8.1622
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
